3-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-4,5-dihydro-1,2,4-oxadiazol-5-one

Catalog No. :
ACRNFY320
CAS No. :
1022600-40-3
Molecular Formula :
C14H7ClF3N3O3
Molecular Weight :
357.67

IUPAC Name:3-(4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)-1,2,4-oxadiazol-5(4H)-one

3-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-4,5-dihydro-1,2,4-oxadiazol-5-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-4,5-dihydro-1,2,4-oxadiazol-5-one
IUPAC Name3-(4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)-1,2,4-oxadiazol-5(4H)-one
MDL No.MFCD00955407
Molecular FormulaC14H7ClF3N3O3
Molecular Weight357.67
SMILESO=C1NC(C2=CC=C(OC3=NC=C(C(F)(F)F)C=C3Cl)C=C2)=NO1
InChI KeyLPNUEUHUWVJRFV-UHFFFAOYSA-N
Synonym3-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-2H-1,2,4-oxadiazol-5-one
CAS No.1022600-40-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRNFY320 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRNFY320 route product structure diagram
    ACRNFY3201022600-40-3
Inquiry

2. ACRNFY320 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTMQV917 route compound structure diagram
    ACTMQV91775806-84-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRNFY320 route product structure diagram
    ACRNFY3201022600-40-3
Inquiry

Comments (0)